⌕
Vertex Pharmaceuticals · VRTX · Nasdaq
Tenet 55 · Mixed
Compare
$534.20−0.67%At closeTenet 55 · Mixed
$534.20−3.59 (−0.67%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$530.05−4.15 (−0.78%)
After hours: Nov 17, 2026, 7:59 PM ET

Vertex Pharmaceuticals (VRTX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~12.2%/yr (FY21→FY25), net margin 32.9%, and free cash flow (~$3.2B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($B)▲8.9%
12.0
FY21→FY25CAGR +12.2%/yr
Net income ($B)—
4.0
one-off year: see footnoteCAGR +14.0%/yr
Free cash flow ($B)—
3.2
FY21→FY25CAGR +7.3%/yr
Diluted EPS—
15.32
FY21→FY25CAGR +14.2%/yr
What the receipts whisper · what a headline number hides
Share count
−0.7%

259.9mn → 258.0mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$437.6M

+47.0% YoY in FY25 · 3.6% of revenue.

Returns vs FCF
63%

$2.0B returned vs $3.2B of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)12.0Revenue−1.7COGS10.3Gross profit−4.0R&D−1.8SG&A4.2Op income−0.2Tax & other4.0Net income

33¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY21FY25

Over this window: gross 88.1% → 86.2%. Net margin 32.9% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
12,951.612,001.311,020.19,869.28,930.77,574.4▲8.9%+12.2%
Cost of revenue
1,874.11,651.31,530.51,262.21,080.3904.2▲7.9%+16.2%
Gross profit
11,077.510,350.09,489.68,607.07,850.46,670.2▲9.1%+11.6%
Research & development
4,368.74,042.58,258.73,690.02,655.83,051.1▼51.1%+7.3%
Selling, general & admin
2,407.01,753.11,464.31,136.6944.7840.1▲19.7%+20.2%
Total operating expenses
6,773.76,176.79,722.54,775.03,543.03,888.1▼36.5%+12.3%
Operating incomefeeds ROC rank
4,303.84,173.3−232.93,832.04,307.42,782.1—+10.7%
Other income, net
455.3469.9481.4547.8−75.0−51.7——
Pretax income
4,759.14,643.2248.54,379.84,232.42,730.4▲1768.5%+14.2%
Income tax
783.2690.0784.1760.2910.4388.3▼12.0%+15.5%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
3,975.93,953.2−535.63,619.63,322.02,342.1—+14.0%
Per share
Diluted EPSbuyback-sensitive
15.5315.32−2.0813.8912.829.01—+14.2%
Diluted shares (mn)
255.20258.00257.90260.50259.10259.90▲0.0%−0.2%
Margins
Gross margin79th pct in Healthcare
85.5%86.2%86.1%87.2%87.9%88.1%▲0.1pp−1.8pp
Operating margin
33.2%34.8%−2.1%38.8%48.2%36.7%▲36.9pp−2.0pp
Net margin95th pct in Healthcare
30.7%32.9%−4.9%36.7%37.2%30.9%▲37.8pp+2.0pp
† TTM = trailing four quarters through 2026-09-30.FY24 effective tax rate was 316% vs a 17% norm for this window, likely a one-time item; see the filing.
FY08 – FY20 · 13 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 13 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-13 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Vertex Pharmaceuticals' revenue last fiscal year?

Vertex Pharmaceuticals reported revenue of $12.0B in fiscal 2025, up 8.9% from fiscal 2024.

What was Vertex Pharmaceuticals' net income?

Vertex Pharmaceuticals reported net income of $4.0B in fiscal 2025, a net margin of 32.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.